Development and Validation of a Nomogram for Preoperative Prediction of Lymph Node Metastasis in Lung Adenocarcinoma Based on Radiomics Signature and Deep Learning Signature

Jia Ran†, Ran Cao†, Jiumei Cai‡, Tao Yu‡,3 Dan Zhao‡,3* and Zhongliang Wang†*

Background and Purpose: The preoperative LN (lymph node) status of patients with LUAD (lung adenocarcinoma) is a key factor for determining if systemic nodal dissection is required, which is usually confirmed after surgery. This study aimed to develop and validate a nomogram for preoperative prediction of LN metastasis in LUAD based on a radiomics signature and deep learning signature.

Materials and Methods: This retrospective study included a training cohort of 200 patients, an internal validation cohort of 40 patients, and an external validation cohort of 60 patients. Radiomics features were extracted from conventional CT (computed tomography) images. T-test and Extra-trees were performed for feature selection, and the selected features were combined using logistic regression to build the radiomics signature. The features and weights of the last fully connected layer of a CNN (convolutional neural network) were combined to obtain a deep learning signature. By incorporating clinical risk factors, the prediction model was developed using a multivariable logistic regression analysis, based on which the nomogram was developed. The calibration, discrimination and clinical values of the nomogram were evaluated.

Results: Multivariate logistic regression analysis showed that the radiomics signature, deep learning signature, and CT-reported LN status were independent predictors. The prediction model developed by all the independent predictors showed good discrimination (C-index, 0.820; 95% CI, 0.762 to 0.879) and calibration (Hosmer-Lemeshow test, P=0.193) capabilities for the training cohort. Additionally, the model achieved satisfactory discrimination (C-index, 0.861; 95% CI, 0.769 to 0.954) and calibration (Hosmer-Lemeshow test, P=0.775) when applied to the external validation cohort.
INTRODUCTION

Lung cancer is the most common cancer worldwide and the leading cause of cancer-related death (1). NSCLC (Non-small cell lung cancer) is the most common type of lung cancer, and adenocarcinoma is the most common subtype of NSCLC (2, 3). Studies showed that most cancer patients die of cancer cell metastasis (4). In lung cancer, Lymph node metastasis is the most common way of metastasis (5). In the recent decades, SND (systematic nodal dissection), as a core method for evaluating node involvement levels at the mediastinal and hilar, has been accepted by the IASLC (International Association for Lung Cancer Research) as a key component of intrathoracic staging (6). However, for patients with no LN metastasis, SND has no other benefits except to prove that their pathological state is N0, which obviously leads to unnecessary invasive treatment. In addition, SND prevents the lymphatic fluid in the influenced area from being discharged, thereby resulting in lymphedema. This then leads to over-treatment. It is therefore important to develop a preoperative, non-invasive, and effective method to predict the extent of LN involvement.

Imaging methods, such as CT and PET (positron emission tomography), are commonly used in clinical LN diagnosis. CT can diagnose lymph nodes based on their size, but it cannot detect small LN metastasis. In PET imaging, LN metastasis usually shows increased FDG (Fludeoxyglucose) uptake, but inflammation and infection can also contribute to this. Compared with imaging methods, imaging-guided biopsy has better sensitivity and specificity in identifying LN metastasis, but it may lead to complications such as pneumothorax and bleeding (7–10). In recent years, radiomics has provided alternative ways for the diagnosis and prognosis of cancer (11–13). Some studies have successfully used radiomics features to predict LN metastasis in lung cancer (14, 15). In addition, thanks to the development of computer hardware and algorithms, deep learning has achieved great success in the field of computer vision (16). The model developed by deep learning has been successfully applied to the detection of skin cancer, diabetic retinopathy, breast cancer and so on (17–20). There are also studies related to deep learning in the diagnosis of lymph nodes of lung cancer (21, 22). However, few studies used both radiomics and deep learning to predict LN metastasis.

Therefore, the purpose of this study is to develop and validate the effectiveness of a nomogram (23) with a radiomics signature, deep learning signature, and clinical risk factors for the preoperative prediction of LN metastasis in patients with LUAD.

MATERIALS AND METHODS

Patients and Data Acquisition

We retrospectively collected the data of 300 patients with LUAD from the Liaoning Cancer Hospital over the period of April 2015 to July 2019. We randomly divided 300 patients into the training cohort, internal validation cohort, and external validation cohort in equal proportions. In total, the training cohort included 200 patients: 99 males and 101 females; mean age, 63.21 ± 6.82. Internal validation cohort included 40 patients (18 males and 22 females; mean age, 64.35 ± 6.69). External validation cohort included 60 patients (27 males and 33 females; mean age, 63.18 ± 6.94). The baseline clinicopathological data included age, sex, CT-reported LN status, and CEA (carcinoembryonic antigen). However, owing to the lack of CEA data in more than half of the patients, CEA was abandoned. The inclusion and exclusion criteria of the data were as follows. Inclusion criteria: (a) the LN status was confirmed by operation and pathology reports, (b) the focus was single nodal mass type, (c) the time interval between CT scan and operation was no more than 1 month, (d) the slice thickness of CT plain scan image was 5 mm. Exclusion criteria: (a) preoperative radiotherapy or chemotherapy, (b) central lesions in the lung, (c) atelectasis and consolidation, (d) history of other tumors. The workflow of the study is illustrated in Figure 1.

Before CT scanning, foreign metal bodies were removed from the upper body of the patient to avoid the problem of artifacts. The patient was asked to raise his/her arms across the top of his/her head in the supine position and remain fixed in this position. The scanning was performed from the entrance of the chest to the diaphragm, when both the body and mind of the patient were in a relaxed state. The scanning machine used was Philips iCT 256 (Netherlands), and it had the following parameters: tube voltage of 120 kVp; 3D tube current in the range 110–325 mAs; layer thickness of 5.0 mm; acquisition matrix of 512 × 512; and, the FOV (field of view) was affected by the body fat and adjusted for thickness. The CT-reported LN status was determined by the radiologists based on the clinical

Abbreviations: CNN, Convolutional neural network; CT, computed tomography; FDG, Fludeoxyglucose; FOV, field of view; IASLC, International Association for Lung Cancer Research; LUAD, lung adenocarcinoma; LN, lymph node; NRI, net reclassification improvement; PET, positron emission tomography; ROI, region of interest.
The presence of either regional LN of >1 cm and/or clusters of ≥3 lymph nodes was scored as LN-positive, and otherwise as LN-negative. The ROI (region of interest) was delineated by the radiologist according to the maximum cross-sectional area of the tumor boundary. CEA was obtained by a routine blood test and laboratory analysis within one week before operation. A CEA <5 ng/mL was recorded as normal, and otherwise as abnormal.

Statistical Analysis
For determining the differences in the distribution of variables between cohorts, we used Kruskal-Wallis rank sum test to analyze the continuous variables (age, radiomics signature, deep learning signature) and chi-square test to analyze the discrete variables (sex, CT-reported LN status). Furthermore, for determining the correlation between variables and LN status within the cohort, we used Wilcoxon rank sum test to analyze the continuous variables and chi-square test or Fisher exact test to analyze the discrete variables. All the statistical tests in the study were two-sided with a significance level of 0.05.

Building the Radiomics Signature and Deep Learning Signature
Pyradiomics (24) was used to extract features from the ROI. T-test was used to select features with a statistical significance of \( P < 0.05 \), and Extra-trees was used to further select features with rich information from the training cohort. Then, logistic regression (25) was used to weight and combine the selected features, which built the radiomics signature. The extracted features and their weighting coefficients were applicable to the internal as well the external validation cohorts.

VGG-16 was used to build the deep learning signature. We first used each tumor slice and its adjacent two slices as R, G and B channels respectively, and combined them to obtain a three-channel image. Then an 80x80 pixel size area containing the tumor was cropped out as the final image input to VGG-16. As the amount of data collected was small, we used data augmentation to increase the amount of data and transfer learning to make the model easier to converge. Data augmentation technology included rotation, horizontal and vertical displacement, horizontal and vertical flipping, cropping, and scaling of the image. Transfer learning involved taking the pretraining weights of VGG-16 on the ImageNet dataset as the initial weights of the model, and then fine-tuning the model using the data of our training and internal validation cohorts. Next, the features of the last fully connected layer of VGG-16 were combined with weights and biases as the feature of each tumor image. The average value of the feature of multiple tumor images was calculated as the deep learning signature of the patient.

Development of the Prediction Model
The candidate features of the multivariate logistic regression analysis included age, gender, CT-reported LN status, radiomics signature, and deep learning signature. The Akaike information criterion (26) was used as the stop criterion to determine the best
features using a stepwise backward method. Additionally, the prediction model developed using logistic regression for the training cohort was also suitable for the internal as well as the external validation cohorts. Then, we developed a nomogram based on the developed prediction model.

**Performance of the Prediction model**

The calibration curve and Hosmer-Lemeshow test (27) were used for model calibration. To quantify the discrimination, we calculated the C-index of the prediction model, and to compare the performance of the multi-factor model and the single-factor model, the NRI (net reclassification improvement) was calculated. In addition, we calculated the additional NRI of 5-fold cross-validation to obtain more reliable results.

Decision curve analysis (28) was used to quantify the net benefit at different threshold probabilities in the external validation cohort to determine the clinical value of the prediction model.

**RESULTS**

**Clinical Characteristics**

The characteristics of all the cohorts are listed in Table 1. Because the data were divided into the different cohorts in equal proportions, the probability of LN metastasis was 50% in all the cohorts (P= 1.000). Furthermore, there was no significant difference observed with regard to gender among all the cohorts (P= 0.763), as was the case with the CT-reported LN status (P= 0.475) and age (P= 0.551). This indicated that the division of data was effective. Radiomics signature (P= 0.996) and deep learning signature (P= 0.869) also showed good reproducibility in all the cohorts (Supplementary Material and Table S1).

| Characteristic | Training Cohort | Internal Validation Cohort | External Validation Cohort |
|---------------|-----------------|----------------------------|---------------------------|
|                | LN Metastasis (+) | LN Metastasis (-) | P | LN Metastasis (+) | LN Metastasis (-) | P | LN Metastasis (+) | LN Metastasis (-) | P |
| Age, years    | 62.97 ± 6.47     | 63.45 ± 7.19          | 0.842 | 64.75 ± 6.66   | 63.96 ± 6.88          | 0.684 | 63.00 ± 7.32 | 63.37 ± 6.67 | 0.830 |
| Gender, No. (%) | 54(54.0)        | 45(45.0)              | 0.258 | 11(55.0)       | 7(35.0)               | 0.340 | 18(40.0)   | 9(30.0) | 0.038* |
| Male          | 46(46.0)        | 55(45.0)              |         | 9(45.0)        | 13(65.0)              |         | 12(40.0)  | 21(70.0) | 0.010* |
| Female        | 49(49.0)        | 55(55.0)              |         |             |                      |         |           |         |       |
| CT-reported LN status, No. (%) | <0.001* | <0.001* | 0.002* | 0.010* | 0.001* | 0.001* | 0.001* | 0.001* |
| LN-negative   | 63(63.0)        | 85(85.0)              | <0.001* | 12(60.0)      | 2(10.0)               | <0.001* | 14(53.3)  | 4(13.3) | <0.001* |
| LN-positive   | 37(37.0)        | 15(15.0)              |         |             |                      |         |           |         |       |
| Radiomics signature, median | 0.529 | -0.577 | 0.718 | -0.657 | 0.731 | -0.718 | (0.100 to 1.236) | (1.376 to 0.250) | (0.421 to 1.165) | (1.468) |
| (interquartile range) | (-0.034 to 1.120) | (-1.169 to 0.298) | (-0.023 to 1.035) | (-1.411 to -0.023) | (-0.131 to 0.479) | (-0.153 to 0.479) | (0.462) |
| Deep learning signature, median | 0.670 | 0.227 | 0.667 | 0.121 | 0.770 | 0.199 | (0.440 to 1.002) | (0.989) | (0.498 to 0.823) | (0.479) |
| (interquartile range) | (0.052 to 1.120) | (0.095 to 0.479) | (0.421 to 1.165) | (0.479) | (0.421 to 1.165) | (0.466) |

Univariate Analysis of Clinical Features and Lymph Node Status. Wilcoxon rank sum test was performed on continuous variables. Chi-square test was used for discrete variables whose theoretical frequency was greater than or equal to 5, and Fisher exact test was used for those less than 5.

*P value < .05.
Development of the Prediction Model

Multivariate logistic regression analysis confirmed that radiomics signature, deep learning signature, and CT-reported LN status were independent predictors (Table 2). The model combining the above-mentioned independent predictors was developed and presented in the form of a nomogram (Figure 4). The specific method for estimating the LN metastasis probability is explained in the Supplementary Material (Equation S1).

Performance of the Prediction Model

The calibration curve (Figure 5) of the nomogram showed that there was a good agreement between the prediction and observation results in the training cohort ($P = 0.193$), indicating no deviation from the perfect fit. The nomogram also showed good agreement in the internal ($P = 0.468$) as well as the external ($P = 0.824$) validation cohorts. Furthermore, it showed good discrimination capability for all the cohorts, and the C-index of nomogram in the training cohort, internal validation cohort and external validation cohort was 0.820 (95% CI, 0.762 to 0.879), 0.830 (95% CI, 0.694 to 0.966) and 0.861 (95% CI, 0.769 to 0.954) respectively.

To measure the improvement of the multi-factor nomogram over other single-factor prediction models, the NRI was calculated for the external validation cohort. Based on the results, it was confirmed that the nomogram showed a significant improvement compared with the model built using only radiomics signature (IDI, 0.297; $P < 0.001$; NRI (Categorical), 0.267 and NRI (Continuous), 1.067). The NRI results of an additional 5-fold cross-validation also showed that the multi-factor model was significantly improved compared to the single-factor model (Supplementary Material, Table S2). This proved that the deep learning signature was helpful for improving the performance of the prediction model.

The decision curve showed that if the threshold probability of determining the presence of LN metastasis was greater than 0.18, using nomogram to predict LN metastasis will benefit more than all the treatment plans or no treatment plan at all (Figure 6).

DISCUSSION

In this study, we developed and validated a nomogram based on a radiomics signature, deep learning signature, and CT-reported LN status for the preoperative prediction of LN metastasis in patients with LUAD.

For constructing the radiomics signature, the total number of features (1288) was reduced to 528 using the T-test, and then 8 features with rich information were selected using Extra-trees. Extra-trees is an ensemble learning method, which is composed of multiple decision tree. Extra-trees reduces the risk of overfitting a single model. Therefore, the features selected by Extra-trees are robust. Then, we used logistic regression to combine features to obtain the radiomics signature.

Considering that deep learning achieves better results than traditional machine learning methods in ImageNet large-scale Visual recognition Challenge, this study also used deep learning method. The difference between radiomics method and deep learning method...
The learning method is that the extracted features are different. The features extracted by the deep learning method are automatically learned by the model from the data, while the features extracted by the radiomics method are artificially defined. These two approaches have their own advantages and disadvantages. For the deep learning method, if the amount of data is large enough, the features it learns can explain the data well, but when the amount of data is small, the features it learns can’t explain the data well. For the radiomics method, the features extracted by it are not affected by the amount of data, but by artificial experience. Limited artificial experience makes it difficult for radiomics method to achieve very good diagnostic results. The combination of radiomics features and deep learning features can integrate the advantages of both. Therefore, in this study,

**TABLE 2 | Risk factors for LN metastasis in LUAD**

| Intercept and Variable | Model 1 | | Model 2 | | Model 3 | | Model 4 |
|------------------------|---------|--------|---------|--------|---------|--------|
|                       | $\beta$ | Odds Ratio (95% CI) | $P$ | $\beta$ | Odds Ratio (95% CI) | $P$ | $\beta$ | Odds Ratio (95% CI) | $P$ | $\beta$ | Odds Ratio (95% CI) | $P$ |
| Intercept              | -0.004  | 0.982  | 1.211  | <0.001 | -0.300  | 0.072  | -1.031  | 0.001  | 1.088  | 2.967  | <0.001  | 0.669  | 1.951  | 0.002  |
| Radiomics signature    | 1.088   | 2.967  | (2.122 to 4.327) | <0.001 | NA      | NA      | (1.299 to 3.010) | 0.002 | NA     | 1.598  | 4.944   | 0.001  | (1.968 to 13.239) |
| Deep learning signature| 1.088   | 2.967  | (2.122 to 4.327) | <0.001 | NA      | NA      | (1.299 to 3.010) | 0.002 | NA     | 1.598  | 4.944   | 0.001  | (1.968 to 13.239) |
| CT-reported LN status  | 1.202   | 3.238  | (1.710 to 6.748) | <0.001 | 0.868   | 2.383  | 0.025  | (1.127 to 5.194) |
| C-index                | 0.777   | (0.713 to 0.841) | 0.777 | (0.713 to 0.841) | 0.610 | (0.551 to 0.669) | 0.682 | (0.762 to 0.879) | 0.820 | (0.762 to 0.966) | 0.830 | (0.694 to 0.966) | 0.861 | (0.769 to 0.954) |

$\beta$ is the coefficient of logistic regression. Odds ratio means the rate of change of occurrence of the event when the other factors remain unchanged and this factor changes by a single unit. NA means not available.

![FIGURE 3](image_url) | Heat map of VGG. Grad-cam showed the region of interest of the VGG, which was also the region where the features were extracted by the VGG. The closer the color is to yellow, the more important is the region.
Both deep learning features and radiomics features were used to predict LN metastasis of lung adenocarcinoma. However, different from some studies, we didn’t directly output thousands of features of the last fully connected layer, but combined the features with its weights and biases to get a deep learning signature (30, 31). This helped to draw nomogram and analyze the individual influence of deep learning features on LN metastasis.

Because the amount of data is relatively small, this study used data augmentation technology and transfer learning technology in deep learning. Data augmentation technology expanded the amount of data. Transfer learning technology made the training of VGG-16 easier. Specifically, we took the pretraining weights of VGG-16 on ImageNet as the initial weights of the model, and then used our data to fine-tune the model.

Multivariate logistic regression analysis showed that radiomics signature, deep learning signature and CT-reported LN status were independent and effective predictors. The c-index of the nomogram constructed with these three features in the training cohort, the internal validation cohort and the external validation cohort was respectively 0.820 (95% CI, 0.762 to 0.879), 0.830 (95% CI, 0.694 to 0.996), 0.861 (95% CI, 0.769 to 0.954), which was better than any single-factor model. The results of NRI showed that nomogram was significantly improved compared with the single-factor model.

The limitations of this study mainly include the following: (a) No enough clinical information. Smoking history and CEA have been proved to be effective predictors of LN metastasis (14, 15); (b) No genetic information was used. Some studies have shown that in the primary tumor, miR-31, miR-34b/c, miR-148 and miR-9-325 were significantly correlated with LN status (32, 33). Incorporating genetic features may improve the performance of the radiomics model, which may be a future research direction; (c) The amount of data is relatively small. The more the amount of data, the features learned by the deep learning method can better explain the data; (d) This is a single-center retrospective study. A prospective multicenter clinical trial is needed to validate our model.
In summary, this study proposes a nomogram based on radiomics signature, deep learning signature, and CT-reported LN status that can be conveniently used to predict preoperative LN metastasis in patients with LUAD.

DATA AVAILABILITY STATEMENT

The data analyzed in this study is subject to the following licenses/restrictions: The datasets are privately owned by Liaoning Cancer Hospital and are not made public. Requests to access these datasets should be directed to DZ, zhaodan777@126.com.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Medical Ethics Committee of Cancer Hospital of Liaoning Province, China. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2018. CA Cancer J Clin (2018) 68(1):7–30. doi: 10.3322/caac.21442
2. Selamat SA, Chung BS, Girard L, Girard L, Zhang W, Zhang Y, et al. Genome-scale Analysis of DNA Methylation in Lung Adenocarcinoma and Integration With mRNA Expression. Genome Res (2012) 22(7):1197–211. doi: 10.1101/gr.132662.111
3. Coroller TP, Grossmann P, Hou Y, Velazquez ER, Leijenaar RTH, Hermann–G, et al. CT-Based Radiomic Signature Predicts Distant Metastasis in Lung Adenocarcinoma. Radiother Oncol (2015) 114(3):345–50. doi: 10.1016/j.radonc.2015.02.015
4. Allemani C, Matsuda T, Di Carlo V, Carlo VD, Harewood R, Matz M, Nikšić M, et al. Global Surveillance of Trends in Cancer Survival 2000-14 (Concord-3): Analysis of Individual Records for 37 513 025 Patients Diagnosed With One of 18 Cancers From 322 Population-Based Registries in 71 Countries. Lancet (2018) 391(10125):1023–75. doi: 10.1016/S0140-6736(17)33326-3
5. Lu Y, Ma T, Wang L, Xue T. Advances in Lymph Node Metastasis and Lymph Node Dissection in Early Non-small Cell Lung Cancer. Zhongguo Fei Ai Za Zhi (2019) 22(8):520–5. doi: 10.3779/j.issn.1009-3419.2019.08.07
6. Goldstraw P. Report on the International Workshop on Intrathoracic Staging, London, October 1996. Lung Cancer (1997) 18(1):107–11. doi: 10.1016/S0169-5002(97)00051-2

AUTHOR CONTRIBUTIONS

JR, RC, JC, DZ, and ZW conceived and designed the concept. JC, TY, and DZ collected the data. JR and RC analyzed the data. All authors contributed to the article and approved the submitted version.

FUNDING

This study was supported by the National Key Research and Development Program of China (Nos. 2017YFC1309100), and the Science and Technology Program of Liaoning Province (No. 2018225038).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.585942/full#supplementary-material
7. Stamatis G. Staging of Lung Cancer: The Role of Noninvasive, Minimally Invasive and Invasive Techniques. *Eur Respir J* (2015) 46(2):521–31. doi: 10.1183/09031936.0158-1796

8. Toloza EM, Harpole L, McCrory DC. Noninvasive Staging of non-Small Cell Lung Cancer: A Review of the Current Evidence. *Chest* (2003) 123(1):137S–46S. doi: 10.1378/chest.123.1_suppl.137s

9. Yang H, Zhang Y, Wang KP, Ma Y. Transbronchial Needle Aspiration: Development History, Current Status and Future Perspective. *J Thorac Dis* (2015) 7(S4):S279–86. doi: 10.3978/j.issn.2072-1439.2015.11.36

10. Masszone P, Jain P, Arroliga AC, Matthay RA. Bronchoscopy and Needle Biopsy Techniques for Diagnosis and Staging of Lung Cancer. *Clin Chest Med* (2002) 23(1):137–58. doi: 10.1016/s0272-5231(03)00065-0

11. Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout RGPM, Granton P, et al. Radiomics: Extracting More Information From Medical Images Using Advanced Feature Analysis. *Eur J Cancer* (2012) 48(4):441–6. doi: 10.1016/j.ejca.2011.11.036

12. Gillies RJ, Kinahan PE, Hricak H. Radiomics: Images are More Than Pictures, They are Data. *Radiol. (2016)* 278(2):563–77. doi: 10.1148/radiol.2015115169

13. Lambin P, Leijenaar RTH, Deist TM, Peerlings J, van Timmeren J, et al. Radiomics: The Bridge Between Medical Imaging and Personalized Medicine. *Nat Rev Clin Oncol* (2017) 14(12):749–62. doi: 10.1038/nrclinonc.2017.141

14. Cao J, Yang F, Jiang G, Li J, Wang J. Development and Validation of a Clinical Prediction Model for N2 Lymph Node Metastasis in non-Small Cell Lung Cancer. *Ann Thorac Surg* (2013) 96(5):1761–8. doi: 10.1016/j.athoracsur.2013.06.038

15. Jiang L, Jiang S, Lin Y, Yang H, Xie Z, Lin Y, et al. Nomogram to Predict Occult N2 Lymph Nodes Metastases in Patients With Squamous Nonsmall Cell Lung Cancer. *Medicine* (2015) 94(46):e2054. doi: 10.1097/MD.000000000002054

16. Pendleton SD, Andersen H, Du X, Shen X, Meghani M, Eng YH, et al. Perception, Planning, Control, and Coordination for Autonomous Vehicles. *Machines* (2017) 5(1):6. doi: 10.3390/machines5010006

17. Lijens G, Kooi T, Bejnordi BE, Setio AAA, Ciompi F, Ghafoorian M, et al. A Survey on Deep Learning in Medical Image Analysis. *Med Image Anal* (2017) 42:60–88. doi: 10.1016/j.media.2017.07.005

18. Esteva A, Kuprel B, Novoa RA, Ko J, Swetter SM, Blau HM, et al. Dermatologist-Level Classification of Skin Cancer With Deep Neural Networks. *Nature* (2017) 542(7639):115–8. doi: 10.1038/nature21056

19. McKinney SM, Sienniek M, Godbole V, Godwin J, Antropova N, Ashrafian H, et al. International Evaluation of an AI System for Breast Cancer Screening. *Nature* (2020) 577(7788):89–94. doi: 10.1038/s41586-019-1799-6

20. Gulshan V, Peng L, Coram M, Stumpe MC, Wu D, Narayanaswamy A, et al. Development and Validation of a Deep Learning Algorithm for Detection of Diabetic Retinopathy in Retinal Fundus Photographs. *JAMA* (2016) 316 (22):2402–10. doi: 10.1001/jama.2016.17216

21. Zhao X, Wang X, Xia W, Li Q, Zhou L, Li Q, et al. A Cross-Modal 3D Deep Learning for Accurate Lymph Node Metastasis Prediction in Clinical Stage T1 Lung Adenocarcinoma. *Lung Cancer* (2020) 145:10–7. doi: 10.1016/j.lungcan.2020.04.014

22. Pham HHN, Futakuchi M, Bychkov A, Furukawa T, Kuroda K, Fukuouka J. Detection of Lung Cancer Lymph Node Metastases From Whole-Slide Histopathologic Images Using a Two-Step Deep Learning Approach. *Am J Pathol* (2019) 189(12):2428–39. doi: 10.1016/j.ajpath.2019.08.014

23. Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in Oncology: More Than Meets the Eye. *Lancet Oncol* (2015) 16(4):e173–80. doi: 10.1016/S1470-2045(14)71116-7

24. van Griethuysen J, Fedorov A, Parmar C, Hosny A, Aucoin N, Narayan V, et al. Computational Radiomics System to Decode the Radiographic Phenotype. *Cancer Res* (2017) 77(21):1047–4. doi: 10.1158/0008-5472.CAN-17-0339

25. Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O, et al. Scikit-Learn: Machine Learning in Python. *J Mach Learn Res* (2013) 12 (10):2825–30. doi: 10.1524/auto.2011.0951

26. Sauerbrei W, Boulesteix AL, Binder H. Stability Investigations of Multivariable Regression Models Derived From Low- and High-Dimensional Data. *J Biopharm Stat* (2011) 21(6):1206–31. doi: 10.1080/10543406.2011.629890

27. Hosmer DW, Lemeshow S. Goodness-of-Fit Tests for the Multiple Logistic Regression Model. *Commun Stat-Theor M* (1980) 9(10):1043–69. doi: 10.1080/03610928008827941

28. Vickers AJ, Elkin EB. Decision Curve Analysis: A Novel Method for Evaluating Prediction Models. *Med Decis Making* (2006) 26(6):565–74. doi: 10.1177/0272989X06293636

29. Selvaraju RR, Cogswell M, Das A, Vedantam R, Parikh D, Batra D. Grad-Cam: Visual Explanations From Deep Networks Via Gradient-Based Localization. *Int J Comput Vis* (2020) 128(2):336–59. doi: 10.1007/s11263-019-01228-7

30. Lao J, Chen Y, Li ZC, Li Q, Zhang J, Liu J, et al. A Deep Learning-Based Radiomics Model for Prediction of Survival in Glioblastoma Multiforme. *Sci Rep* (2017) 7(1):10353. doi: 10.1038/s41598-017-10649-8

31. Li Z, Wang Y, Yu J, Guo Y, Cao W. Deep Learning Based Radiomics (DLR) and its Usage in Noninvasive IDH1 Prediction for Low Grade Glioma. *Sci Rep* (2017) 7(1):5467. doi: 10.1038/s41598-017-05848-2

32. Fazi F, Fornèmaggì G. MicroRNAs and Lymph Node Metastatic Disease in Lung Cancer. *Thorac Surg Clin* (2012) 22(2):167–75. doi: 10.1016/j.thorsurg.2011.11.001

33. Meng W, Ye Z, Cui R, Perry J, Dedousi-Huebner V, Huebner A, et al. MicroRNA-31 Predicts the Presence of Lymph Node Metastases and Survival in Patients With Lung Adenocarcinoma. *Clin Cancer Res* (2013) 19(19):5423–33. doi: 10.1158/0878-0432.CCR-13-0320

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Ran, Cao, Cui, Yu, Zhao and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.